Valbonne, France, October 2, 2017, 5.45pm CEST
TxCell SA (FR0010127662 – TXCL), a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, today announces it will present two posters with new CAR-Treg related data at the 25th Anniversary Congress of the European Society of Gene & Cell Therapy (ESGCT) to be held on October 17-20, 2017 in Berlin, Germany.
- Combination of transduction enhancers with Ecotropic-MLV pseudotyped lentiviral vectors enables highly efficient transfer of chimeric antigen receptors into murine T effector and T regulatory lymphocytes, Fenard D (presenting author), David M, Abel T, Marchetti I, Asnagli H, Zhou L and Meyer F, Poster session 2, October 19, 2017, 5.40-8pm.
In this poster, David Fenard, PhD, Director Gene Transfer at TxCell, will present TxCell’s strategy to genetically modify murine T cells – both effector T cells (Teffs) and regulatory T cell (Tregs) – with a lentiviral vector.
- Designing the next generation of chimeric Antigen receptors for Regulatory T cell therapy through in silico modeling-guided single chain Fv engineering, Abel T (presenting author), Schneider IC, Beghelli S, Labbal F, David M, Zhou M and Meyer F, Poster session 2, October 19, 2017, 5.40-8pm.
In this poster, Tobias Abel, PhD, Manager CAR Engineering at TxCell, will present the design of TxCell’s next-generation CARs for regulatory T cell therapy, using in silico modeling-guided single-chain variable fragment (scFv) engineering. This follows the oral presentation and poster delivered at the CAR-TCR Summit by Li Zhou, PhD, Vice President Cell Engineering at TxCell, in September 2017.
Abstracts will be made available on October 17, 2017 both on TxCell’s website www.txcell.com in the Technology/Publications & Abstracts section as well as on the conference website www.esgct.eu/congress.aspx.